<DOC>
	<DOC>NCT01585155</DOC>
	<brief_summary>The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity index (CAI) score and other evaluation indicators in pediatric patients with moderate to severe ulcerative colitis after TA-650 administration of at a dose of 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks at weeks 14 and 22. The safety and pharmacokinetics are also evaluated.</brief_summary>
	<brief_title>Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients who have been diagnosed as ulcerative colitis at least 3 months prior to screening. Have active ulcerative colitis despite adequate conventional therapy. Patients who have severe pancolitis. Patients who have undergone surgery for ulcerative colitis within 8 weeks before enrollment or who were judged to require surgery for ulcerative colitis at enrollment. Patients who have a history of treatment with infliximab or other biologic products (antiTNFÎ± agents, antiIL6 agents, etc.).</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
</DOC>